Navigation Links
Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
Date:12/2/2008

BASKING RIDGE, N.J., Dec. 2 /PRNewswire/ -- Regado Biosciences, Inc., announced today the appointment of Ellen McDonald to the newly created position of Senior Vice President of Business Operations and Chief Business Officer, effective immediately. Ms. McDonald brings to Regado nearly 20 years of experience in the biopharmaceutical industry, with expertise heading business development, operations, portfolio management and marketing. She will report to David J. Mazzo, Ph.D., the Company's President and Chief Executive Officer.

Dr. Mazzo stated, "Ellen has made critical contributions to Regado as a senior consultant, and we are very pleased to announce she is joining the Company's management team. She has a substantial track record in building commercial enterprises and in spearheading the growth of pharmaceutical product portfolios. These capabilities will be invaluable as we further accelerate our lead therapeutic programs." Regado recently completed enrollment in a Phase IIa clinical study (REVERSAL-PCI) of its most advanced therapeutic candidate, the REG1 Anticoagulation System, in patients undergoing elective percutaneous coronary intervention.

Most recently, Ms. McDonald served as Senior Vice President and Chief Business Officer at Aeterna Zentaris, and, prior to that, Senior Vice President, Business Operations at Chugai Pharma USA. At both firms, she had a key role in establishing new directions for the enterprise and facilitating relationships with the financial community. Previously, Ms. McDonald served as Senior Vice President, Cardiovascular Marketing and Medical at Bristol-Myers Squibb, managing a $4.25 billion portfolio of cardiovascular products and a budget of $400 million. She was responsible for leading the growth in sales of Plavix(R), the second-largest-selling drug in the world last year, Pravachol(R) and Avapro(R). Ms. McDonald began her career in the pharmaceutical industry at Johnson & Johnson, where she rose to the leadership of the company's largest pharmaceutical franchise as Vice President, Oncology at Ortho Biotech.

Ms. McDonald is a Director of Cobalis Corporation and a member of the Women's Foreign Policy Group. She earned a Bachelor of Science in General Engineering at the United States Military Academy, West Point, following which she served for five years abroad with the U.S. Army. She also earned a Masters of Business Administration in the Executive Program at Columbia University.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic field with the creation and development of two-component drug systems, comprising an aptamer therapeutic that can be controlled directly by its specific and matched reversal agent. Regado's technology is designed to give physicians the ability to directly control and titrate each system's therapeutic effect. Enhanced control and flexibility allow physicians to meet the individual needs of patients independent of the setting. Regado is focusing its discovery and development efforts on acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control.

Current investors in Regado include Domain (Princeton, NJ), Quaker BioVentures (Philadelphia, PA), Aurora Funds (Durham, NC) and Caxton Advantage Life Sciences Fund (New York, NY), as well as individual investors, including Robert Kierlin.


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Call for Applications: The Amgen Award for Science Teaching Excellence
2. Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show
3. Robert L. Brent, MD, PhD, Honored with 2008 Alfred I. duPont Award for Excellence in Childrens Health Care
4. MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research
5. Early-Bird Registration Ends this Week for 10th Annual Quality Excellence Conference: How Process Improvement Leaders Produce Profits in Recessions
6. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
7. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
8. Workforce Alliance Receives U.S. Labor Departments Excellence Award
9. University of Miami Miller School of Medicine Becomes a GeneGo Center of Excellence
10. ATS Medical Confirms Excellent Durability of the ATS Open Pivot Mechanical Heart Valve
11. Yale Keck Microarray Center Becomes a GeneGo Center of Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... TIKVAH, Israel , April 20, 2017 /PRNewswire/ ... adult stem cell technologies for neurodegenerative diseases, announced today that ... the Alliance for Regenerative Medicine,s (ARM) 5 th Annual ... 2017 at 09:40 EDT in Boston . ... MHSc, Chief Medical Officer & Chief Operating Officer, will participate ...
(Date:4/19/2017)... ... April 18, 2017 , ... ... has been a key device for generating monodisperse droplets of known diameters for ... and for generating monodisperse solid particles by drying monodisperse droplets. , The ...
(Date:4/19/2017)... ... ... Alisa Wright, founder and CEO of Singota Solutions , has received ... Lafayette, Indiana. , The Distinguished Alumni Award was established in 1984 to honor ... endeavors. , Wright began her career in the pharmaceutical industry with firms such ...
(Date:4/19/2017)... , ... April 19, 2017 , ... Nobilis Therapeutics ... , Company Seeks to Leverage Clinical Data in its Upcoming Post Traumatic Stress Disorder ... of an 81 patient clinical trial assessing efficacy of its NBTX-001, a xenon-based therapeutic ...
Breaking Biology Technology:
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):